Dr. Jagannath on Sequencing Therapies for Patients With Multiple Myeloma

Sundar Jagannath, MD
Published: Wednesday, Mar 02, 2016



Sundar Jagannath, MD, director of the Multiple Myeloma Program, professor of Medicine (Hematology and Medical Oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses sequencing challenges with therapies for patients with multiple myeloma.

It is imperative to first understand the patient population being treated, Jagannath explains. Oncologists should take into consideration if the patient is elderly, has renal impairment, is experiencing ongoing toxicities from a prior therapy, or has thrombocytopenia. They should also be aware of myeloma-related challenges, including rapidly progressive disease, extramedullary disease, and central nervous system and liver metastases. Exposure to prior therapies should also be considered.

There is no one-size-fits-all approach to selecting or sequencing therapies for patients with myeloma, Jagannath insists.



Sundar Jagannath, MD, director of the Multiple Myeloma Program, professor of Medicine (Hematology and Medical Oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses sequencing challenges with therapies for patients with multiple myeloma.

It is imperative to first understand the patient population being treated, Jagannath explains. Oncologists should take into consideration if the patient is elderly, has renal impairment, is experiencing ongoing toxicities from a prior therapy, or has thrombocytopenia. They should also be aware of myeloma-related challenges, including rapidly progressive disease, extramedullary disease, and central nervous system and liver metastases. Exposure to prior therapies should also be considered.

There is no one-size-fits-all approach to selecting or sequencing therapies for patients with myeloma, Jagannath insists.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x